Dean Eliott, M.D.
|Associate Director, Retina Service|
Macular Degeneration Unit
Mass. Eye and Ear
243 Charles Street
Boston, MA 02114
Mass. Eye and Ear Retina Consultants
3 Woodland Road, Suite 210
Stoneham, MA 02180
|Medical School||Vanderbilt University School of Medicine|
|Residency||Ophthalmology, Wilmer Ophthalmological Institute/Johns Hopkins Hospital|
|Fellowship||Vitreoretinal Surgery, Duke University Medical Center|
|Teaching Affiliation||Stelios Evangelos Gragoudas Associate Professor of Ophthalmology, Harvard Medical School|
Dr. Eliott attended Duke University as an undergraduate, moving on to Vanderbilt University School of Medicine. He then completed his ophthalmology residency at Wilmer/Johns Hopkins Hospital where he served as Chief Resident. This was followed by a vitreoretinal fellowship at Duke and six years on the faculty at Kresge Eye Institute in Detroit. Before coming to Mass. Eye and Ear, Dr. Eliott was Professor of Ophthalmology, Director of Clinical Affairs, and Director of Vitreoretinal Fellowship at the USC Keck School of Medicine’s Doheny Eye Institute in Los Angeles.
As a clinical innovator and clinician scientist, Dr. Eliott has a particular interest in implantable and sustained-release steroid devices and vision-restoring electrical devices. Actively engaged in bringing new medications and devices from the bench to the bedside, he has a long history of research funding from both government and industry sources for clinical multicenter trials.
Research and Clinical Interests
Diabetic retinopathy, macular degeneration, retinal detachment, surgery for retina-vitreous disorders and ocular trauma
Yonekawa Y, Hacker HD, Lehman RE, Beal CJ, Veldman PB, Vyas NM, Shah AS, Wu D, Eliott D, Gardiner MF, Kuperwaser MC, Rosa RH Jr, Ramsey JE, Miller JW, Mazzoli RA, Lawrence MG, Arroyo JG. Ocular blast injuries in mass-casualty incidents: The marathon bombing in Boston, Massachusetts, and the fertilizer plant explosion in West, Texas. Ophthalmology. 2014 May 17.
Channa R, Sophie R, Khwaja AA, Do DV, Hafiz G, Nguyen QD, Campochiaro PA; READ-2 Study Group. Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. Eye (Lond). 2014 Mar;28(3):269-78.
Gentile RC, Eliott D. Silicone oil retention sutures in aphakic eyes with iris loss. Arch Ophthalmol. 2010 Dec; 128(12): 1596-9.
VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology. 2006 Sep; 113 (9):1508.e1-25.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 Oct 5; 355(14): 1419-31.